Effect of clinical progress in antihypertensive medications among COVID-19 patients Antihypertensive medications among COVID-19 patients

Main Article Content

Mehmet Kara
Ilhami Celik

Abstract

Objective: Many chronic diseases, such as hypertension, diabetes, and coronary heart disease, paving the way for the disease to progress unfavorably in Covid-19. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-2 receptor blockers (ARBs) can upregulate ACE2 receptors (which SARS-COV-2 uses to enter the host cell) or protect against infection by limiting the effects of Angiotensin 2. This study aimed to reveal the impact of antihypertensive drugs on the hospital staying, and mortality in Covid-19 patients followed in the hospital.


Methods and Results: One hundred patients were randomly selected with hypertension, diabetes mellitus and coronary artery disease hospitalized in Kayseri City Training and Research Hospital due to Covid-19 infection. Patients were grouped as taking ACEIs and ARBs group and not taking ACEIs and ARBs group. There were no differences among the groups in terms of the frequency of chronic disease and treatment modalities. The length of the hospital stays, bedding into the Intensive Care Unit (ICU), and mortality rates were higher in the group without ACEIs or ARBs. Mortality was significantly lower among patients who used ACEIs and ARBs (P=0.00, P=0.02, respectively) and incredibly high among beta-blocker users (P=0.00).  It was found that the advanced age, male gender and use of beta-blockers were associated with mortality.


Conclusion: Although antihypertensive medications are allegedly associated with increased mortality rates, the risk of mortality has not been detected in people taking ACEIs and ARBs. Further studies involving a greater number of patients are needed.

Downloads

Download data is not yet available.

Article Details

How to Cite
Kara, M., & Celik, I. (2022). Effect of clinical progress in antihypertensive medications among COVID-19 patients: Antihypertensive medications among COVID-19 patients. Medical Science and Discovery, 9(10), 593–598. https://doi.org/10.36472/msd.v9i10.829
Section
Research Article
Received 2022-10-13
Accepted 2022-10-22
Published 2022-10-24

References

Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13): 1239-1.

Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019- nCoV. J Med Virol. 2020 May; 92(5):491-494.

Kuba, K., Imai, Y., Rao, S., et al. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature medicine, 11(8), 875-879..

Baral, R., Tsampasian, V., Debski, et al. (2021). Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. J.

Zhang, P., Zhu, L., Cai, J., et al. (2020). Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with.

Armstrong K, Soltoff A, Rieu-Werden M et al. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts. PLoS One. 2021 Mar 2;16(3):e0247548.

Wang, W., Zhao, X., Wei, W., et al. (2021). Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients. BMC infectious diseases, 21(1), 1-8..

Lubel J, Garg M. Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19. N Engl J Med. 2020 Jun 11;382(24): e92.

Vasanthakumar N. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients. Bioessays. 2020 Nov;42(11):e2000094.

Al-Kuraishy, Al-Gareeb, Mostafa-Hedeab, et al. (2021). Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19. Frontiers in Immunology, 12.

Clemente-Moragón, A., Martínez-Milla, J., Oliver, E., et al. (2021). Metoprolol in critically ill patients with COVID-19. Journal of the American College of Cardiology, 78(10), 1001-1011.

Palaiodimos, L., Kokkinidis, Li, W., Karamanis, D., et al. (2020). Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality.

Cecconi, M., Piovani, D., Brunetta, E., et al. (2020). Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy. Journal of clinical med.

Tomar B, Anders HJ, Desai J, et al. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19. Cells. 2020 Jun 2;9(6):1383.

Li, C., Hu, B., Zhang, Z., et al. (2020). D‐dimer triage for COVID‐19. Academic Emergency Medicine, 27(7), 612-613.